Clinical Trial

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

Study acronym: UCL-Xenog
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2015-10-08; most recent amendment 2024-12-02.
Trial Details
NCT Number NCT02572778
Lead Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions Squamous Cell Carcinoma of the Head and Neck
Enrollment 40 participants
Start Date 2015-09
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-03